Filter by: patients
Home > Community Treatment Reports and Side Effects > Travoprost Treatment Report
What is Travoprost?

Travoprost is a prostanoid agonist used to treat eye conditions, such as glaucoma and ocular hypertension, in which increased pressure can cause a gradual loss of vision. It comes as an eyedrop to apply to the eye.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Glaucoma 9 1 Efficacy_moderate
Glaucoma (Both eyes) 5 0
Other 2 0
Diagnostic assessment 1 0
Doctor recommendation 1 0

See all 17 patients currently taking Travoprost

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 0
Mild
 0
None
 1

Reported Dosages

  0.004 g daily 0.004% daily 0.008 g daily 1 other daily
  13 Number of Patients: 13 2 Number of Patients: 2 1 Number of Patients: 1 1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Taking Travoprost (multiple reasons could be selected)
Reason # Patients Percentage of patients
Doctor's advice 2   Doctor's advice: 67%
Expense 1   Expense: 33%
Not indicated 1   Not indicated: 33%

See all 3 patients who’ve stopped taking Travoprost

Reported Duration See details about how long patients take this treatment ▼

Currently Taking Travoprost

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0

Stopped Taking Travoprost

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Travoprost

Always
 0 0%
Usually
 1 100%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of Travoprost

Very
 0 0%
Somewhat
 0 0%
A little
 0 0%
Not at all
 1 100%

Cost

Paid out of pocket

Cost of Travoprost

$200+
 0 0%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 1 100%
< $25
 0 0%

Report created on May 28, 2012.